|
Pimecrolimus okayed for mild, moderate Eczema: New topical immunomodulator adds heft to armamentarium for common disease. (Use in Infants Promising).
Publication: Skin & Allergy News Publication Date: 01-JAN-02 Author: Brunk, Doug
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2002 International Medical News Group
The Food and Drug Administration has approved pimecrolimus for the treatment of mild to moderate atopic dermatitis in patients aged 2 years and older.
The product, which Novartis Pharmaceuticals plans to bring to market in March under the trade name Elidel, is approved for short-term and intermittent long-term treatment in patients who fail to respond to therapy with topical corticosteroids.
Pimecrolimus 0.1% cream is the second product in the new class of nonsteroidal macrolide immunomodulators. The first, tacrolimus...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Skin & Allergy News |
Sutures superior to glue for cosmetic outcome. (Pediatric Population).
January 01, 2002
|
Rhytidectomy with tisseel glue means less discomfort. (No Suction Drai...
January 01, 2002
|
Nd: YAG laser significantly clears PFB lesions. (Small Study).
January 01, 2002
|
Cooling expands lasers' usefulness. (Treating Darker Skin).
January 01, 2002
|
Implanted hardware calls for presurgical prophylaxis. (Conservative Ap...
January 01, 2002
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
